Can I Take Resveratrol With Vyleesi (Bremelanotide)?

The direct answer

There is no documented pharmacokinetic drug interaction between resveratrol and bremelanotide (Vyleesi) in the FDA prescribing information or in FDA's public post-marketing adverse event dashboard as of May 2026. Bremelanotide is administered by subcutaneous injection and is cleared primarily through hydrolysis rather than hepatic cytochrome P450 metabolism, which is the pathway that oral resveratrol is reported to modulate. The clinically relevant question is not enzyme interference but whether combining a supplement associated with blood-pressure-lowering effects with a drug that causes a known transient blood pressure rise could widen blood pressure swings in an individual patient, a scenario that has not been directly studied and should be discussed with a prescriber, especially for anyone with existing hypertension or cardiovascular disease.

How bremelanotide works, and why that shapes the interaction picture

Bremelanotide activates MC4R receptors in brain regions linked to sexual arousal signaling. It is FDA-approved for premenopausal women with acquired, generalized HSDD, and it is used on-demand rather than daily, injected roughly 45 minutes before anticipated sexual activity. According to the FDA label, peak plasma concentration occurs about an hour after injection with a terminal half-life of a few hours.

Because bremelanotide is delivered subcutaneously and is a peptide, it largely bypasses the gastrointestinal absorption and first-pass liver metabolism that oral drugs go through. This is the central reason resveratrol's reported cytochrome P450 effects have limited practical relevance here: the interaction concern that matters most for many oral drug pairings, competition at a liver enzyme, applies less when the drug in question does not depend on that enzyme for clearance.

The CYP3A4 question, and why it probably does not apply here

Laboratory studies have reported that resveratrol can inhibit CYP3A4 activity in vitro, at concentrations of resveratrol that are higher than what typically circulates in blood after an oral supplement dose. Resveratrol also undergoes extensive first-pass metabolism itself, and human pharmacokinetic studies have found that only a small fraction of an oral dose reaches systemic circulation as free, unmetabolized resveratrol. That combination, low CYP3A4-inhibiting drug levels achieved in vivo, plus a target drug that is not primarily CYP-metabolized, is why this specific pairing is unlikely to produce a clinically meaningful pharmacokinetic interaction, even though the isolated laboratory finding is real.

This is a case where "pharmacologically plausible in a test tube" and "clinically relevant in a person taking both products" diverge. Readers should not read the in-vitro CYP3A4 data as proof of a real-world interaction, and they should not read the absence of listed interactions as proof there is none. Neither has been directly tested in a trial combining these two specific agents.

Blood pressure: the overlap that deserves real attention

This is the part of the pairing most worth watching. The FDA prescribing information for Vyleesi describes a transient increase in blood pressure following injection, and it states that Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Small randomized trials of resveratrol supplementation have reported modest blood-pressure-lowering effects in some populations, though effect sizes have varied across studies and doses, and this article does not restate a specific pooled number here because the underlying trial identifiers could not be verified against the primary literature for this draft.

The practical concern is not that the two effects simply cancel out. If resveratrol lowers a person's resting blood pressure and bremelanotide then produces its known transient rise, the net swing in either direction could be larger or more variable than either agent alone would produce, particularly in someone also taking antihypertensive medication. This has not been studied directly in a trial that combined both agents, so the concern is a reasoned inference from each drug's individual profile, not an established finding.

Estrogenic activity: a weaker concern

Resveratrol is often described as a phytoestrogen because it has been shown in laboratory studies to bind estrogen receptors, with reported affinity for estrogen receptor beta stronger than for estrogen receptor alpha. Bremelanotide does not act on estrogen receptors; its mechanism is centrally mediated through melanocortin receptors. Because the two drugs work through unrelated receptor systems, and because oral resveratrol supplementation produces relatively low systemic concentrations of free resveratrol, a meaningful hormonal interaction between the two is not established and is considered less likely than the blood pressure overlap discussed above.

Evidence-status interaction assessment

Practical timing and monitoring guidance

No published guideline specifies a required separation window between resveratrol and bremelanotide. The following is a reasonable, conservative approach based on how each drug is absorbed, not a validated clinical protocol.

• Taking resveratrol with a morning or midday meal, and reserving bremelanotide for on-demand evening use as is typical for HSDD treatment, creates a natural gap of several hours between the two.
• If both are needed closer together, separating doses by at least two hours avoids overlapping peak absorption windows.
• On any day both agents are used, checking blood pressure before the bremelanotide injection and again one to three hours afterward can catch an unusually large swing early.
• A systolic reading above 160 mmHg, a diastolic reading above 100 mmHg, a new or worsening headache within a few hours of injection, or severe nausea are reasons to contact a prescriber before repeating the combination.
• Anyone with uncontrolled hypertension should not use Vyleesi at all, per the FDA label, independent of supplement use. Anyone taking two or more antihypertensive medications should discuss any added supplement, including resveratrol, with the prescriber managing their blood pressure before combining it with Vyleesi.

What interaction databases and post-marketing data show

A general-purpose supplement-drug interaction database (Natural Medicines) is a reasonable place to check for an updated listing, though this article does not restate a specific classification language from that source because it could not be independently verified for this draft; readers and clinicians should check the current monograph directly. FDA's public FAERS dashboard, which tracks post-marketing adverse event reports, showed no apparent signal specific to this combination as of May 2026. That absence is reassuring but not conclusive, since supplement co-use is frequently not captured in adverse event reports.

Evidence boundary: what this page can and cannot tell you

Established: Vyleesi's FDA label describes its blood pressure effect and its contraindications. Bremelanotide's elimination route is hydrolysis rather than CYP-dependent metabolism, per its labeling. No FDA-labeled interaction with resveratrol exists, and no adverse event signal for the combination has surfaced in public FAERS data as of this writing.

Plausible but unproven: that resveratrol's blood-pressure-lowering tendency and bremelanotide's blood-pressure-raising tendency could interact in a given patient to produce a larger or more variable swing than either alone; that resveratrol's CYP3A4 inhibition is too weak at typical oral supplement doses to matter for a drug that does not depend on that pathway.

Not established: any effect of resveratrol on Vyleesi's effectiveness; a validated timing or dosing protocol for combining the two; how this pairing behaves in patients on antihypertensive therapy, since no trial has tested it directly.

This article is general information for premenopausal women prescribed Vyleesi who are considering or already using resveratrol. It is not individualized dosing or diagnostic advice. Anyone with uncontrolled blood pressure, cardiovascular disease, or a complex medication regimen should review this specific combination with the prescriber managing their Vyleesi prescription, and with a pharmacist if multiple medications are involved.